ClinicalTrials.gg
Not yet recruitingNCT07842965Updated Sep 25, 2026

CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial

A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver and Stage IV Colorectal Cancer AJCC v8, sponsored by City of Hope Medical Center. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing floxuridine in Colorectal Neoplasms — 5 open to participants now, 6 under way, 3 of them phase 3. Floxuridine · Colorectal Neoplasms.

Planned enrollment
18th of 25
36 · median 49
Started
2027
the only one that year
Phase 1
4 of 27
1 open now
Registered
27th of 27
by date
Lead sponsor
2 of 27
City of Hope Medical Center

Among the 27 studies testing floxuridine in Colorectal Neoplasms, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2027, is one of 4 in phase 1, and was the 27th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 27 studies testing floxuridine in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About floxuridine

Floxuridine: first FDA approval 1970 (FUDR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing floxuridine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This phase I/Ib trial tests the effect of leronlimab in combination with hepatic arterial infusion (HAI) floxuridine (FUDR)and standard of care (SOC) systemic therapy in treating patients with colorectal cancer that has spread from where it first started to the liver (metastatic). Leronlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets, such as CCR5 which is expressed on T cells (a type of immune cell), which may cause the body to make an immune response (antigens) and may also improve the effectiveness of treatment. HAI delivers chemotherapy, such as floxuridine, directly to the liver. Catheters are put into an artery in the groin that leads directly to the liver and drugs are given through the catheters. Floxuridine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of tumor cells in your body. HAI can deliver floxuridine at up to 300 times the concentrations that can be given through the vein. Systemic therapy is treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body. Giving leronlimab in combination with HAI floxuridine and SOC systemic therapy may be safe, tolerable, and/or safe in treating colorectal cancer patients with liver metastases.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the feasibility of administering four planned cycles of combined standard-of-care systemic therapy, hepatic arterial infusion (HAI) floxuridine (FUDR), and leronlimab as reflected by relative dose intensity in the study population.

SECONDARY OBJECTIVES:

I. To characterize the safety profile of the combined regimen. II. To evaluate the anti-tumor activity of leronlimab administered subcutaneously alongside HAI pump and systemic therapy in patients with colorectal cancer with liver metastases, as assessed by 1 year and 2 year progression-free survival (PFS) and median progression free-survival.

III. To evaluate liver-specific disease control with leronlimab plus HAI pump and systemic therapy.

IV. To evaluate the anti-tumor activity of Leronlimab administered subcutaneously alongside HAI pump and systemic therapy in patients with colorectal cancer with liver metastases, as assessed by changes in circulating tumor deoxyribonucleic acid (DNA) (ctDNA) and ctDNA clearance.

EXPLORATORY OBJECTIVES:

I. To characterize baseline and on-treatment tissue and circulatory biomarkers of immune evasion and metastatic potential, including PD-L1 expression, immune genomic and phenotypic biomarkers, and circulating tumor cells.

II. To assess liver damage and healing associated with leronlimab plus HAI pump and systemic therapy.

III. To evaluate standard-of-care imaging findings and liver parenchyma for evidence of liver damage and disease progression.

OUTLINE:

Patients receive leronlimab subcutaneously (SC) weekly with SOC systemic therapy for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection with HAI pump placement. Starting 4 weeks after surgery, patients receive floxuridine continuously via HAI pump every 14 days of each cycle and resume leronlimab SC weekly in combination with SOC systemic therapy of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and computed tomography (CT) and/or magnetic resonance imaging (MRI) throughout the study. Additionally, patients may optionally undergo biopsy on study.

After completion of study treatment, patients are followed up at 30 days and then for up to 24 months.

03

Conditions studied

  • Metastatic Colorectal Carcinoma
  • Metastatic Malignant Neoplasm in the Liver
  • Stage IV Colorectal Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • Agreement to allow the use of from diagnostic tumor and/or surgical biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: ≥ 18 years
  • (ECOG) ≤ 2
  • Confirmed colorectal cancer with liver dominant metastases amenable and a candidate for adjuvant HAI floxuridine (FUDR) pump therapy as determined by the clinical team.

    • Note: patients should be candidates for an R0/R1 complete resection of the liver metastases with the goal of ideally achievement of no evidence of disease (NED) or treated disease
    • Note: peri/intra-operative interventional ablation therapy, radiation therapy, as well as liver-directed therapy to achieve NED/treated disease is allowed. Patients who are getting a liver pump only and no surgery due to unresectable liver metastases are not eligible for this study
  • ≥ 8 g/dL (within 14 days prior to day 1 of protocol therapy)

    • NOTE: Iron replacement and/or red blood cell transfusions are permitted as long as the patient is not actively bleeding
  • Total ≤ 1.5 x (ULN) (unless has Gilbert's syndrome) (within 14 days prior to day 1 of protocol therapy)

    • NOTE: If the patient has Gilbert's disease, (AST) and alanine aminotransferase (ALT) must be ≤ 3.0 x ULN
  • AST ≤ 5.0 x ULN (within 14 days prior to day 1 of protocol therapy)
  • ALT ≤ 5.0 x ULN (within 14 days prior to day 1 of protocol therapy)
  • Creatinine ≤ 1.5 x institutional ULN (within 14 days prior to day 1 of protocol therapy) OR

    • ≥ 50 mL/min calculated by the Cockcroft-Gault method
  • Women of (WOCBP): negative urine or serum pregnancy test (within 14 days prior to day 1 of protocol therapy)

    • If the urine test is positive or cannot be confirmed as negative, a qualitative or quantitative serum pregnancy test will be required
  • Agreement by females and males of childbearing potential to use an effective method of or abstain from heterosexual activity for the course of the study through at least three months after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in another interventional study. Participation in observational clinical studies is permitted
  • Chemotherapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy

    • Note: Radiation therapy and/or other peri/intra-operative other liver directed therapy is allowed; patients need to have sufficiently recovered from it as assessed by the treating physician or site PI
  • Patients using herbal medications or supplements. These also need to be stopped 14 days prior to day 1 of protocol therapy. Exceptions are over-the-counter medications or supplements taken for supportive care (e.g., vitamins, ginseng or electrolytes for fatigue) are permitted. Participants will be advised to discuss with the study team prior to initiating any new medication or supplement during the study
  • Significant comorbidities or conditions that would impede candidacy for surgery or trial participation
  • Known to leronlimab or components of the formulation
  • Other active . Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Treatment (leronlimab, HAI FUDR, systemic therapy)

    Patients receive leronlimab SC weekly with SOC systemic therapy for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection with HAI pump placement. Starting 4 weeks after surgery, patients receive floxuridine continuously via HAI pump every 14 days of each cycle and resume leronlimab SC weekly in combination with SOC systemic therapy of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study. Additionally, patients may optionally undergo biopsy on study.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Floxuridine · Procedure: Intrahepatic Infusion Procedure · Biological: Leronlimab · Procedure: Magnetic Resonance Imaging · Procedure: Surgical Procedure · Procedure: Systemic Therapy

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given via HAI pump

    Also known as: 2'-Deoxy-5-fluorouridine, 5-Fluoro-2'-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR 138720, WR-138720, WR138720

  • ProcedureIntrahepatic Infusion Procedure

    Given floxuridine via HAI pump

    Also known as: HAI, Hepatic Arterial Infusion, Hepatic Artery Infusion, IHI, Intrahepatic Infusion

  • BiologicalLeronlimab

    Given SC

    Also known as: PA14, PRO 140, PRO-140, PRO140, WHO 10751

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureSurgical Procedure

    Undergo surgical resection with HAI pump placement

    Also known as: Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

  • ProcedureSystemic Therapy

    Given SOC systemic therapy

    Also known as: Non-targeted, Non-targeted Therapy, Systemic Treatment

06

What researchers measure

Primary outcomes

  1. Proportion of patients completing all four planned hepatic arterial infusion (HAI) cycles with a relative dose intensity ≥ 80% for HIA floxuridine (FUDR)

    Will be calculated using the number of patients who complete all four planned HAI cycles with a relative dose intensity ≥ 80% for HAI FUDR divided by the total number of enrolled patients.

    Time frame: Up to 4 cycles (cycle length = 28 days)

Secondary outcomes

  1. Incidence, type, and severity of adverse events (AEs) attributed to HAI

    Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose HAI through 30 days after the last dose of HAI

  2. Incidence of serious AEs attributed to HAI

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose HAI through 30 days after the last dose of HAI

  3. Incidence of AEs attributed to HAI leading to treatment interruption or discontinuation

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose HAI through 30 days after the last dose of HAI

  4. Incidence, type, and severity of AEs attributed to leronlimab

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose leronlimab through 30 days after last dose of leronlimab

  5. Incidence of serious AEs attributed to leronlimab

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose leronlimab through 30 days after last dose of leronlimab

  6. Incidence of AEs leading attributed to leronlimab to treatment interruption or discontinuation

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose leronlimab through 30 days after last dose of leronlimab

  7. Incidence, type, and severity of AEs attributed to systemic therapy

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose systemic therapy through 30 days after last dose of systemic therapy

  8. Incidence of serious AEs attributed to systemic therapy

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose systemic therapy through 30 days after last dose of systemic therapy

  9. Incidence of AEs attributed to systemic therapy leading to treatment interruption or discontuation

    Will be graded according to CTCAE v 5. Events will be summarized by frequency, system organ class, preferred term, worst grade, and attribution category. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first dose systemic therapy through 30 days after last dose of systemic therapy

  10. Incidence and extent of liver toxicity attributed to HAI/FUDR requiring dose reductions based on standard of care nomogram

    Data will be summarized by incidence, indication, dose delays, dose interruptions, additional intraarterial corticosteroid doses administered, duration of additional intraarterial corticosteroid therapy, and association with treatment hold, dose reduction, or permanent discontinuation of HAI/FUDR. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From the first HAI infusion through 30 days after the final dose of HAI therapy

  11. Incidence and characteristics of dose reductions and treatment interruption of HAI/FUDR therapy

    Dose reductions will be summarized by incidence, number of dose reductions per patient, time to first dose reduction, primary reason for dose reduction, and lowest dose level reached and whether treatment was subsequently discontinued. Descriptive statistics will be used to summarize the safety profile.

    Time frame: From first administration of HAI therapy and up through 30 days after the final administration of HAI therapy

  12. Radiographic progression free survival (PFS)

    Will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Will be summarized as the proportion of patients who meet definition. Will be graphically represented using Kaplan-Meier methods.

    Time frame: From enrollment to first objective occurrence of tumor progression or death due to any cause, whichever occurs first, assessed up to 1 year

  13. Radiographic PFS

    Will be assessed using RECIST v 1.1. Will be summarized as the proportion of patients who meet the definition. Will be graphically represented using Kaplan-Meier methods.

    Time frame: From enrollment to first objective occurrence of tumor progression or death due to any cause, whichever occurs first, assessed up to 2 years

  14. Median PFS

    Will be graphically represented using Kaplan-Meier methods.

    Time frame: Up to 24 months

  15. Median liver-PFS

    Will be graphically represented using Kaplan-Meier methods.

    Time frame: Up to 24 months

  16. Liver-PFS

    Will be graphically represented using Kaplan-Meier methods.

    Time frame: From enrollment to the first occurrence of radiographic progression within the liver or death due to any cause, assessed up to 1 year

  17. Liver-PFS

    Will be graphically represented using Kaplan-Meier methods.

    Time frame: From enrollment to the first occurrence of radiographic progression within the liver or death due to any cause, assessed up to 2 years

  18. Change in circulating tumor deoxyribonucleic acid (ctDNA)

    Change in ctDNA will be quantified as the difference between the baseline value and each subsequent measurement. Proportion achieving clearance defined as 100% reduction in the ctDNA will also be reported. Will be quantitatively assessed to determine their correlation with clinical outcomes/findings.

    Time frame: At baseline (weeks 0, 2, 4, and 6) and post operatively (weeks 2, 4, 6, 8, 10, 12, 14 and 16)

  19. ctDNA clearance

    Will be quantitatively assessed to determine their correlation with clinical outcomes/findings

    Time frame: Up to 24 months

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Feb 2028, 8 months later.

Of 166 non-industry phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 8 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartEst.
May 6, 2027
Primary completionEst.
Feb 2, 2028
CompletionEst.
Feb 2, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07842965
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
May 6, 2027 (estimated)
Primary completion
Feb 2, 2028 (estimated)
Completion
Feb 2, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Pashtoon M Kasi
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Floxuridine · Leronlimab

Start the discussion